B-cell Therapy for Multiple Sclerosis: Entering an era-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

B-cell Therapy for Multiple Sclerosis: Entering an era

Published:2018-01 Issue:1 Volume:83 Page:13-26
ISSN:0364-5134
Container-title:Annals of Neurology
language:en
Short-container-title:Ann Neurol.

Author:

Greenfield Ariele L.¹,Hauser Stephen L.¹

Affiliation:

1. Department of Neurology, Weill Institute for Neurosciences; University of California; San Francisco, San Francisco CA

Funder

National Multiple Sclerosis Society

Kathleen C. Moore Postdoctoral Fellowship

NIH

Conrad N. Hilton Foundation

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference115 articles.

1. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis;Hauser;N Engl J Med,2008

2. Ocrelizumab versus placebo in primary progressive multiple sclerosis;Montalban;N Engl J Med,2017

3. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N Engl J Med,2017

4. The Charcot Lecture | beating MS: a story of B cells, with twists and turns;Hauser;Mult Scler,2015

5. B cells as therapeutic targets in autoimmune neurological disorders;Dalakas;Nat Clin Pract Neurol,2008

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients;Multiple Sclerosis and Related Disorders;2024-09

2. Primary Progressive Multiple Sclerosis—A Key to Understanding and Managing Disease Progression;International Journal of Molecular Sciences;2024-08-11

3. Increased level of GATA3-AS1 long non-coding RNA is correlated with the upregulation of GATA3 and IL-4 genes in multiple sclerosis patients;Molecular Biology Reports;2024-07-30

4. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy;Drug Design, Development and Therapy;2024-07

5. COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab;Annals of Neurology;2024-06-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3